APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Influenza Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Inactivated Influenza Virus Vaccine Industry Research Report 2026

29 December 2025134 pages

Choose your research edition.

Industry ResearchInactivated Influenza Virus Vaccine Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Inactivated Influenza Virus Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Inactivated Influenza Virus Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Inactivated Influenza Virus Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Inactivated Influenza Virus Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Inactivated Influenza Virus Vaccine Market by Company

CSL

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Changchun Institute of Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Johnson & Johnson

Mylan

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Pfizer

Hualan Bio Vaccines Co., Ltd

GSK

Dalian Yalifeng Biopharmaceutical Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

AstraZeneca

Sanofi Pasteur

Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine

Subunit Vaccine

Inactivated Influenza Virus Vaccine Segment by Application

Hospital

Clinic

Inactivated Influenza Virus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Inactivated Influenza Virus Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Inactivated Influenza Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Inactivated Influenza Virus Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Inactivated Influenza Virus Vaccine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Inactivated Influenza Virus Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Inactivated Influenza Virus Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Inactivated Influenza Virus Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application Table 14. Global Inactivated Influenza Virus Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Inactivated Influenza Virus Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. CSL Company Information Table 19. CSL Business Overview Table 20. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. CSL Inactivated Influenza Virus Vaccine Product Portfolio Table 22. CSL Recent Developments Table 23. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information Table 24. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview Table 25. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 27. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments Table 28. Changchun Institute of Biological Products Co., Ltd Company Information Table 29. Changchun Institute of Biological Products Co., Ltd Business Overview Table 30. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 32. Changchun Institute of Biological Products Co., Ltd Recent Developments Table 33. Shanghai Institute of Biological Products Co., Ltd Company Information Table 34. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 35. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 37. Shanghai Institute of Biological Products Co., Ltd Recent Developments Table 38. Johnson & Johnson Company Information Table 39. Johnson & Johnson Business Overview Table 40. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio Table 42. Johnson & Johnson Recent Developments Table 43. Mylan Company Information Table 44. Mylan Business Overview Table 45. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Mylan Inactivated Influenza Virus Vaccine Product Portfolio Table 47. Mylan Recent Developments Table 48. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 49. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 50. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 52. Lanzhou Institute of Biological Products Co., Ltd Recent Developments Table 53. Jiangsu Kangrun Biotechnology Co., Ltd Company Information Table 54. Jiangsu Kangrun Biotechnology Co., Ltd Business Overview Table 55. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 57. Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments Table 58. Jiangsu Jindik Biotechnology Co., Ltd Company Information Table 59. Jiangsu Jindik Biotechnology Co., Ltd Business Overview Table 60. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 62. Jiangsu Jindik Biotechnology Co., Ltd Recent Developments Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Pfizer Inactivated Influenza Virus Vaccine Product Portfolio Table 67. Pfizer Recent Developments Table 68. Hualan Bio Vaccines Co., Ltd Company Information Table 69. Hualan Bio Vaccines Co., Ltd Business Overview Table 70. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 72. Hualan Bio Vaccines Co., Ltd Recent Developments Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GSK Inactivated Influenza Virus Vaccine Product Portfolio Table 77. GSK Recent Developments Table 78. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information Table 79. Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview Table 80. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 82. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments Table 83. Beijing Kexing Biological Products Co., Ltd Company Information Table 84. Beijing Kexing Biological Products Co., Ltd Business Overview Table 85. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 87. Beijing Kexing Biological Products Co., Ltd Recent Developments Table 88. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information Table 89. Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview Table 90. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 92. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio Table 97. AstraZeneca Recent Developments Table 98. Sanofi Pasteur Company Information Table 99. Sanofi Pasteur Business Overview Table 100. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio Table 102. Sanofi Pasteur Recent Developments Table 103. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (K Units) Table 105. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2026) Table 106. Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032) & (K Units) Table 107. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2027-2032) Table 108. Global Inactivated Influenza Virus Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2026) Table 110. Global Inactivated Influenza Virus Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2027-2032) Table 112. North America Inactivated Influenza Virus Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 114. North America Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 115. North America Inactivated Influenza Virus Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Inactivated Influenza Virus Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Inactivated Influenza Virus Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 119. Europe Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 120. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Inactivated Influenza Virus Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 129. South America Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 130. South America Inactivated Influenza Virus Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Inactivated Influenza Virus Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 138. Global Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 139. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2026) Table 140. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2027-2032) Table 141. Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2026) Table 144. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2027-2032) Table 145. Global Inactivated Influenza Virus Vaccine Price by Type (2021-2026) & (US$/Unit) Table 146. Global Inactivated Influenza Virus Vaccine Price by Type (2027-2032) & (US$/Unit) Table 147. Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 148. Global Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 149. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2026) Table 150. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2027-2032) Table 151. Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2026) Table 154. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2027-2032) Table 155. Global Inactivated Influenza Virus Vaccine Price by Application (2021-2026) & (US$/Unit) Table 156. Global Inactivated Influenza Virus Vaccine Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Inactivated Influenza Virus Vaccine Distributors List Table 160. Inactivated Influenza Virus Vaccine Customers List Table 161. Inactivated Influenza Virus Vaccine Industry Trends Table 162. Inactivated Influenza Virus Vaccine Industry Drivers Table 163. Inactivated Influenza Virus Vaccine Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Inactivated Influenza Virus Vaccine Product Image Figure 5. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Inactivated Influenza Virus Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Inactivated Influenza Virus Vaccine Sales (2021-2032) & (K Units) Figure 8. Global Inactivated Influenza Virus Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Whole Virus Vaccine Product Image Figure 10. Subunit Vaccine Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Inactivated Influenza Virus Vaccine Sales by Region in 2025 Figure 19. Global Inactivated Influenza Virus Vaccine Revenue by Region in 2025 Figure 20. North America Inactivated Influenza Virus Vaccine Market Size by Country in 2025 Figure 21. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 22. North America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2021-2032) Figure 23. United States Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Inactivated Influenza Virus Vaccine Market Size by Country in 2025 Figure 26. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 27. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2021-2032) Figure 28. Germany Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Country in 2025 Figure 34. Asia Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2021-2032) Figure 36. China Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Inactivated Influenza Virus Vaccine Market Size by Country in 2025 Figure 45. South America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 46. South America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2021-2032) Figure 47. Mexico Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country in 2025 Figure 51. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2021-2032) Figure 53. Turkey Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Inactivated Influenza Virus Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032) Figure 57. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032) Figure 58. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2021-2032) Figure 59. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032) Figure 60. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032) Figure 61. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2021-2032) Figure 62. Inactivated Influenza Virus Vaccine Value Chain Figure 63. Inactivated Influenza Virus Vaccine Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Whole Virus Vaccine
  • Subunit Vaccine
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL
  • Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  • Changchun Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Johnson & Johnson
  • Mylan
  • Lanzhou Institute of Biological Products Co., Ltd
  • Jiangsu Kangrun Biotechnology Co., Ltd
  • Jiangsu Jindik Biotechnology Co., Ltd
  • Pfizer
  • Hualan Bio Vaccines Co., Ltd
  • GSK
  • Dalian Yalifeng Biopharmaceutical Co., Ltd
  • Beijing Kexing Biological Products Co., Ltd
  • Emmi Chengxin Biopharmaceutical Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Inactivated Influenza Virus Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Inactivated Influenza Virus Vaccine Sales (2021-2032)
  5. 2.2.3 Global Inactivated Influenza Virus Vaccine Market Average Price (2021-2032)
  6. 2.3 Inactivated Influenza Virus Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Whole Virus Vaccine
  9. 2.3.3 Subunit Vaccine
  10. 2.4 Inactivated Influenza Virus Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Inactivated Influenza Virus Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Inactivated Influenza Virus Vaccine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Inactivated Influenza Virus Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Inactivated Influenza Virus Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Inactivated Influenza Virus Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Inactivated Influenza Virus Vaccine, Established Date
  9. 3.9 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 CSL
  2. 4.1.1 CSL Company Information
  3. 4.1.2 CSL Business Overview
  4. 4.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
  6. 4.1.5 CSL Recent Developments
  7. 4.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  8. 4.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
  9. 4.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
  10. 4.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  12. 4.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
  13. 4.3 Changchun Institute of Biological Products Co., Ltd
  14. 4.3.1 Changchun Institute of Biological Products Co., Ltd Company Information
  15. 4.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
  16. 4.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  18. 4.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
  19. 4.4 Shanghai Institute of Biological Products Co., Ltd
  20. 4.4.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  21. 4.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  22. 4.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  24. 4.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  25. 4.5 Johnson & Johnson
  26. 4.5.1 Johnson & Johnson Company Information
  27. 4.5.2 Johnson & Johnson Business Overview
  28. 4.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
  30. 4.5.5 Johnson & Johnson Recent Developments
  31. 4.6 Mylan
  32. 4.6.1 Mylan Company Information
  33. 4.6.2 Mylan Business Overview
  34. 4.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
  36. 4.6.5 Mylan Recent Developments
  37. 4.7 Lanzhou Institute of Biological Products Co., Ltd
  38. 4.7.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  39. 4.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  40. 4.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  42. 4.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  43. 4.8 Jiangsu Kangrun Biotechnology Co., Ltd
  44. 4.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
  45. 4.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
  46. 4.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  48. 4.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
  49. 4.9 Jiangsu Jindik Biotechnology Co., Ltd
  50. 4.9.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
  51. 4.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
  52. 4.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  54. 4.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
  55. 4.10 Pfizer
  56. 4.10.1 Pfizer Company Information
  57. 4.10.2 Pfizer Business Overview
  58. 4.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
  60. 4.10.5 Pfizer Recent Developments
  61. 4.11 Hualan Bio Vaccines Co., Ltd
  62. 4.11.1 Hualan Bio Vaccines Co., Ltd Company Information
  63. 4.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
  64. 4.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  66. 4.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
  67. 4.12 GSK
  68. 4.12.1 GSK Company Information
  69. 4.12.2 GSK Business Overview
  70. 4.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
  72. 4.12.5 GSK Recent Developments
  73. 4.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
  74. 4.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
  75. 4.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
  76. 4.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  78. 4.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
  79. 4.14 Beijing Kexing Biological Products Co., Ltd
  80. 4.14.1 Beijing Kexing Biological Products Co., Ltd Company Information
  81. 4.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
  82. 4.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  84. 4.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
  85. 4.15 Emmi Chengxin Biopharmaceutical Co., Ltd
  86. 4.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
  87. 4.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
  88. 4.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  90. 4.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
  91. 4.16 AstraZeneca
  92. 4.16.1 AstraZeneca Company Information
  93. 4.16.2 AstraZeneca Business Overview
  94. 4.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
  96. 4.16.5 AstraZeneca Recent Developments
  97. 4.17 Sanofi Pasteur
  98. 4.17.1 Sanofi Pasteur Company Information
  99. 4.17.2 Sanofi Pasteur Business Overview
  100. 4.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
  102. 4.17.5 Sanofi Pasteur Recent Developments
5 Global Inactivated Influenza Virus Vaccine Market Scenario by Region
  1. 5.1 Global Inactivated Influenza Virus Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Inactivated Influenza Virus Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Inactivated Influenza Virus Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Inactivated Influenza Virus Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Inactivated Influenza Virus Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
  2. 8.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Inactivated Influenza Virus Vaccine Production Mode & Process
  5. 8.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Inactivated Influenza Virus Vaccine Distributors
  8. 8.2.3 Inactivated Influenza Virus Vaccine Customers
9 Global Inactivated Influenza Virus Vaccine Analyzing Market Dynamics
  1. 9.1 Inactivated Influenza Virus Vaccine Industry Trends
  2. 9.2 Inactivated Influenza Virus Vaccine Industry Drivers
  3. 9.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
  4. 9.4 Inactivated Influenza Virus Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst